Every 8-K that Surrozen, Inc. Warrant (SRZNW) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow SRZNW and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SRZNW filings page.
Surrozen reported Q2 2026 results and updated its ophthalmology pipeline. Collaboration and license revenue was $5.0 million, driven by a milestone from Boehringer Ingelheim. Research and development expenses were $8.5 million and general and administrative expenses $6.9 million. Net income was $50.2 million, including $59.6 million of non-cash gains on tranche and warrant liabilities. Cash and cash equivalents were $102.0 million as of June 30, 2026.
The company plans to submit an IND for SZN-8141 by the end of the third quarter of 2026, initiate the DUET Phase 1b/2a study in diabetic macular edema by year-end 2026, and expects initial DUET data in the second half of 2027. In June 2026 Boehringer Ingelheim achieved a development milestone for SZN-413, and in July 2026 the U.S. Patent Trial and Appeal Board denied institution of Merck’s post-grant review petition challenging a Surrozen patent, reinforcing its intellectual property position.
Surrozen, Inc. reported the results of its 2026 Annual Meeting of Stockholders. Of 11,486,707 shares entitled to vote as of March 18, 2026, 7,744,669 were represented in person or by proxy. Stockholders elected Mace Rothenberg, M.D., and David J. Woodhouse, Ph.D., as Class II directors until the 2029 Annual Meeting, subject to earlier departure. They also ratified Ernst & Young LLP as independent registered public accounting firm for the year ending December 31, 2026. On an advisory basis, stockholders approved the compensation of the named executive officers and chose to hold future advisory votes on executive compensation every year.
Surrozen reported first quarter 2026 results that pair advancing eye-disease programs with heavy non-cash losses tied to financing structures. The company is progressing lead retinal candidates SZN-8141 and SZN-8143 and remains on track to submit an Investigational New Drug application for SZN-8141 in the second half of 2026.
Collaboration and license revenue was $5.0 million, driven by a Boehringer Ingelheim milestone for SZN-413, while cash and cash equivalents rose to $106.9 million as of March 31, 2026 from $89.2 million at year-end. Research and development expenses increased to $9.3 million and general and administrative expenses to $6.1 million as the ophthalmology portfolio scales up.
Net loss widened sharply to $127.5 million, or ($11.65) per share, compared with $27.0 million, or ($7.43) per share, a year earlier. The larger loss primarily reflects a $76.9 million non-cash loss on change in fair value of tranche liability related to the 2025 PIPE and a $41.1 million other expense, mainly from an $81.7 million non-cash increase in warrant liabilities. As of March 31, 2026, tranche liability was $235.5 million and warrant liabilities were $148.9 million, contributing to a stockholders’ deficit of $278.1 million.
Surrozen reported a much larger 2025 net loss but ended the year with significantly more cash and a sharper focus on ophthalmology. Net loss widened to $242.0 million, or ($32.37) per share, from $63.6 million, largely due to non-cash losses tied to a 2025 private placement and related tranche and warrant liabilities.
Cash and cash equivalents rose to $89.2 million as of December 31, 2025, up from $34.6 million a year earlier, helped by equity sales and warrant exercises in early 2026. Total 2025 revenue was $3.5 million, down from $10.7 million, while research and development and general and administrative expenses increased to $29.4 million and $16.2 million, respectively. The company advanced retinal programs SZN-8141 and SZN-8143, expects to file an IND for SZN-8141 in the second half of 2026, and earned a $5.0 million milestone from Boehringer Ingelheim under the SZN-413 partnership, which also includes up to $586.5 million in potential future milestones.
Surrozen, Inc. reported that board member Shao-Lee Lin, M.D., Ph.D. resigned from its Board of Directors, effective immediately on January 26, 2026. The company stated that Dr. Lin’s resignation was not due to any disagreement regarding Surrozen’s operations, policies, or practices. Surrozen expressed appreciation for her service and dedication to the company’s mission.
Surrozen, Inc. entered into a Sales Agreement with TD Securities (USA) LLC (referred to as TD Cowen) that allows the company to sell, from time to time, up to $50.0 million of its common stock through an at-the-market offering. TD Cowen will act as sales agent and/or principal and use commercially reasonable efforts to execute sales based on Surrozen’s instructions, including price, timing, and size parameters. Surrozen will pay TD Cowen a commission of up to 3.0% of the gross sales proceeds for any shares sold, and either party can terminate the agreement by written notice. Any sales will be made under Surrozen’s existing Form S-3 shelf registration, using a base prospectus and an August 29, 2025 prospectus supplement.
Surrozen, Inc. reported by way of a Current Report on Form 8-K that on August 8, 2025 it issued a press release announcing its financial results for the quarter ended June 30, 2025. The press release is attached to the 8-K as Exhibit 99.1 and the filing also includes the Cover Page Interactive Data File (Exhibit 104). The company notes that the information in Item 2.02 and the attached exhibit is not deemed to be "filed" for Section 18 purposes and will not be incorporated by reference into other filings under the Securities Act.
The report lists the company as an emerging growth company and confirms securities registered on Nasdaq: Common Stock (SRZN) and Redeemable warrants (SRZNW). The document is signed by Charles Williams, Chief Financial Officer, Chief Operating Officer and Corporate Secretary.